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The usefulness of DCEs to inform clinical guidelines rests on the assumption that patients facing 
the same treatment choice at different points in time will express the same preferences. This 
study provides the first investigation to our knowledge to specifically focus on the stability of 
patients’ treatment preferences over the course of a clinical trial.   
Methods 
The same Decision Choice Experiment (DCE) was completed by participants at baseline and 
final post-treatment assessment in a trial of the efficacy of alternative topical treatments for 
actinic keratosis as a means for the prevention of skin cancer.  The study assesses both the 
consistency of stated treatment choices and the stability of population-level preference parameter 
estimates, and analyses how the former is influenced by design aspects of the DCE. 
Results 
No evidence is found of population-level preference parameter instability over the course of the 
trial despite only a moderate strength of choice consistency.  Choice consistency is negatively 
related to task difficulty with weak evidence of the existence of ordering effects over the 
sequence of choice tasks. 
Conclusions 
The results provide no evidence that the timing of a DCE within a clinical trial significantly 







i. What is already known about the topic? 
Patients’ treatment preferences are increasingly being elicited using Discrete Choice 
Experiments (DCEs) but there is only limited evidence available on the stability of such 
preferences over the course of a treatment.   
 
ii. What does the paper add to existing knowledge? 
This study is the first to specifically focus on the stability of patients’ treatment preferences over 
the course of a clinical trial. No evidence is found that population-level preference parameters 
change between the baseline and final post-treatment assessments despite only a moderate 
strength of choice consistency. The design of the DCE is shown to affect choice consistency. 
 
iii. What insights does the paper provide for informing healthcare-related decision making? 
The routine incorporation of DCEs into clinical trials would generate information on patient 
treatment preferences to complement existing cost effectiveness analyses in helping shape 
clinical guidelines. The findings of our study provide no evidence that the timing of the DCE 






Discrete Choice Experiments (DCEs) are increasingly being used to elicit patients’ treatment 
preferences in order to take account of healthcare attributes beyond health outcomes.1 The 
usefulness of such DCEs to inform clinical guidelines rests on the assumption that patients facing 
the same healthcare choice at different points in time will express the same preferences, making 
the temporal stability of preferences an important concern. This issue has been addressed in a 
number of previous studies in a variety of decision-making contexts, producing mixed results in 
terms of both the consistency of individual choices and the stability of population-level 
preference parameter estimates over time.2,3 Respondents presented with the same choice set on a 
second occasion are found to choose the same option more often than might be expected by 
chance, but reported levels of agreement in individual choices between repeated surveys range 
from below 60% in Liebe et al. and Schaafsma et al. to over 80% in Ryan et al. and Gamper et 
al.4-7 The first two studies both reject the stability of preference weights whereas the latter two 
are unable to do so. 
 
This paper adds to the existing healthcare literature by providing a study of the temporal stability 
of actinic keratosis (AK) patients’ preferences for topical treatments over the course of a clinical 
trial that investigates the efficacy of alternative skin cancer prevention regimens. In an early 
contribution, San Miguel et al. find that preferences for out-of-hours health care for children do 
not change with service experiences.8 However, the closest comparable study is Skjoldborg et al. 
which explores rheumatoid arthritis patients’ treatment preferences using a DCE that was 
administered three times to the same group of patients with 4 months between each survey to 
minimise possible memory effects.9 Reported choice consistency rates are 76% between the first 




choices in the first two surveys. Choice model estimates of attribute preference weights are not 
found to differ significantly between the surveys. The main aim of this study is to address the 
open question whether patients’ treatment preferences change between the start and end of a 
clinical trial where this might occur as a result of their participation in the trial. 
 
Özdemir et al. (2010) provides a meta-analysis of a number of healthcare DCE studies which 
explores the factors affecting the frequency with which respondents make identical choices when 
presented with the same choice set twice within a single survey.10 A secondary goal of the study 
is to explore the determinants of choice consistency between repeated administrations of the 
same survey, which has not previously been done within a healthcare setting. We focus on the 
difficulty of individual choice tasks as measured by either the entropy of the predicted choice 
probabilities,4 which provides an information theoretic measure of task complexity,11 or the 
difference in predicted utility between the best two choices.12 We also consider the possible 




The research was conducted as part of Squamous cell carcinoma Prevention in Organ transplant 
recipients using Topical treatments (SPOT), a multi-centre, randomised, 3-arm feasibility study 
comparing topical treatments of AK as a strategy for prevention of skin cancer.14 SPOT was 
approved by the Research Ethics Committees of the participating sites and all participants 
provided written informed consent. 
 
The same DCE was administered twice in SPOT, the first time as part of the initial baseline 




assessment to the subset of participants entered into the clinical trial. Kopasker et al. discuss the 
design, piloting and administration of the DCE, which formed part of a written questionnaire 
completed in clinic with a research nurse in attendance to check respondents’ understanding, and 
present preference weight estimates based on the baseline assessment.15 The sample size was 
determined by a power calculation for the main SPOT study, not the DCE, but the Johnson and 
Orme rule of thumb was used to check that this was adequate to detect the main effects in the 
choice model analysis.16 The procedure in the retest assessment was the same as for the baseline 
test.   
 
Participants were presented with a series of choice sets, each consisting of two AK treatment 
alternatives (A and B) with different hypothetical combinations of attribute levels, and a ‘no 
treatment’ opt-out option. Three attributes relate to the burden of medication (treatment regimen, 
severity of local skin reaction, and occurrence of systemic side effects) and two to the efficacy of 
treatment (improvement in skin appearance and reduction in skin cancer risk). Attribute levels 
were comparable to those of currently prescribed creams to ensure clinical relevance, with three 
levels specified for skin cancer risk reduction and two levels each for the four other attributes.   
 
The DCE employed a D-efficient orthogonal main effects plan17 consisting of 12 of the 48 
possible combinations of treatment attribute levels. To validate participant responses, a further 
two choice sets were added to the DCE: the first checked for rationality by specifying one 
treatment option with unambiguously higher medical burden and lower clinical efficacy; the 
second checked for choice consistency by repeating one of the main choice sets but with the 




questionnaires. Importantly, the sequence of choice sets within the DCE was randomly generated 




Choice consistency is measured as the proportion of cases in which respondents make the same 
choice of best option when faced with the same choice set, either within the same DCE or in the 
retest. Cohen’s kappa statistic ( ) ( )1o e ep p p = − − , where op  is the observed agreement rate 
and ep  is the probability of chance agreement, is also calculated to provide an estimate of 
agreement that is corrected for chance.18 Lack of choice consistency within a DCE may arise 
either because choice behaviour is intrinsically stochastic, as is assumed to be the case in random 
utility theory, or due to decision errors resulting from factors such as the limited ability of 
respondents to discriminate between options in a choice set, inattention or fatigue. 
Inconsistencies between repeated DCEs might additionally reflect shifts in preferences. In our 
study, preference changes for treatment attributes may plausibly result from the knowledge and 
experience gained by patients through their participation in the trial. 
 
Preference stability is inferred from the equality of choice model parameter estimates obtained 
from the two assessments, with identification contingent on model specification. We make use of 
a basic multinomial logit (MNL) model incorporating a single alternative-specific constant to 
capture the value of treatment per se. We do not consider more general random parameter logit 
specifications because of the relatively small sample sizes. Thus, the utility that participant i 
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marginal utilities of the treatment attributes kA  included in the DCE; and the set of error terms 
jsi t  are independent and identically Gumbel distributed with standard deviation inversely related 
to the scale parameter  
 
Allowing for the possibility of scale heterogeneity between assessments is important as 
differences in scale can confound identification of differences in preference parameter 
estimates.19,20 To investigate the stability of preferences we first estimate separate MNL models 
for the test and retest samples and a heteroscedastic conditional logit (HCL) model for the pooled 
sample in which the scale parameter is allowed to differ between the two assessments. A 
likelihood ratio test is performed to see if restricting the preference parameters to be equal results 
in a significant deterioration in model fit. As the null hypothesis cannot be rejected we also 
estimate a MNL model for the pooled sample and use these additional results to perform a 
likelihood ratio test of the equality of the scale parameter.   
 




( 1| ,... ) ; 1,... ; 1,...
V
is is Vis i v vis
v
P D x x x i n s S 
=
 
= =  + = = 
 





where variable visx  (v=1,…V) is hypothesised to explain whether the option chosen by 
participant i in choice set s was the same in both assessments ( 1isD = ) or not )( 0isD = . Choice 
consistency is modelled as a function of choice task difficulty and choice set positioning. Our 
preferred measure of the former is given by the entropy of the predicted choice probabilities: 
1 ( )log ( ) 0
J
jsENTROPY P j P j== −  , where ( )P j is the pooled MNL prediction of the probability 
of option j being chosen in choice set s.3,21 We also consider the expected utility difference 
between the best and second best choices as a measure of choice task difficulty,12 where these 
choices are always the two treatment options given the pooled MNL estimates: 
s As BsUDIFF U U= − where Ujs  is the pooled MNL prediction of the utility of option j in choice 
set s. Average choice set position over the two assessments is given by ( ) 2is is isPOSAV P1 P2= + , 
where P1is and P2is are respectively the test and retest positions of choice set s for individual i, 
which will vary across respondents due to the randomisation procedure. isPOSAV  will fully 
capture the influence of choice set position if the marginal impact of position on the value of the 
index function in (2) is constant. To allow for the possibility of non-constant marginal ordering 
effects we also include a position deviation variable ( )2 22 2is is is isPOSDEV P1 P POSAV= + − , 
which takes a minimum value of zero only if a choice set appears in the same position in both 
DCEs and is a decreasing function of average position for any given absolute difference in 
position between the two DCEs. The fixed effects specification fully controls for all time-
invariant patient-specific factors.22 We employ an estimator that incorporates an analytical 







SPOT recruited 109 AK patients: 49 organ transplant recipients (OTRs) to take part in the 
clinical trial and a further 60 immunocompetent patients (ICPs) who only completed the initial 
baseline assessment. This analysis is limited to the OTR subsample of whom one patient, 
wrongly identified as an ICP in Kopasker et al.,15 failed to answer the baseline DCE. Nine OTRs 
were subsequently not entered into the trial with no reason provided in four cases, withdrawal of 
consent in two cases, and one case each due to a requirement for other treatment, failure of 
screening test and deterioration in renal function. Accordingly, the final post treatment sample 
consisted of 40 OTRs, but only 35 completed the final assessment with the DCE left blank in 
four of these cases.   
 
Supplementary Table 1 summarises patient characteristics at baseline. Patients were 
predominantly male with mean age 64. The majority had been most recently diagnosed with AK 
at least three years previously and considered their condition to be moderately serious in nature. 
Most had received prior treatments for AK with 55% reporting previous use of at least one 
topical treatment, specifically 5-fluorouracil cream, imiquimod cream or diclofenac gel. There is 
no evidence of differential attrition over the course of the trial, with no significant differences in 
baseline characteristics between those who did and did not provide retest DCE responses.  
 
Classification of participants by DCE responses 
Table 1 classifies participants by the pattern of their DCE responses in the two assessments. The 
proportions of respondents failing at least one of the validity tests were 17% and 10% in the test 
and retest DCEs respectively. More specifically, the corresponding proportions failing to make 
the same choice of best option in the repeat-choice task were 10% and 6%, yielding a weighted 




passing both tests, 33% and 25% respectively in the two DCEs displayed ‘lexicographic’ choice 
behaviour – choosing the alternative that was the best with respect to one particular attribute in 
all 12 main choice sets – although only one respondent displayed such behaviour in both 
assessments. Following common practice,24 respondents were excluded from the choice model 
analysis if they made either invalid or lexicographic choices, leaving those who passed both tests 
and revealed a willingness to trade gains in one attribute against losses in another at the levels 
specified in the DCE. These ‘traders’ accounted for 55% and 68% of DCE respondents 
respectively in the two assessments, with the 13 individuals who were willing to trade in both 
DCEs representing 27% of test and 42% of retest respondents. 
 
Choice consistency 
Table 2 presents choice consistency statistics. Choices are counted as consistent if a respondent 
made the same choice of best option in a choice set in both assessments, and inconsistent 
otherwise (including two instances where no choice was indicated in one of the assessments). 
The gross level of agreement is 73.1%, implying that respondents chose the same best option on 
average in 8.77 of the 12 main choice sets. This is higher than expected by chance, with the 
Cohen’s Kappa of 0.469 indicating a ‘moderate’ strength of agreement according to the 
commonly cited Landis and Koch benchmarks.25 However, agreement rates differ markedly 
across respondents with the least consistent only making identical choices in 4 sets (i.e. 33% 
agreement) and the most consistent in 11 (92%). A subgroup analysis based on Fisher’s exact 
test revealed no significant association between agreement rates and a tripartite classification of 
respondents by DCE responses in the two assessments [p=0.936]. Moreover, average agreement 




one assessment compared to either those who made lexicographic choices in at least one 
assessment [t=−0.659, p=0.511] or traders in both assessments [t=−0.988, p=0.324].  
 
Population-level preference parameter estimates
Table 3 presents choice model estimation results. The positive estimates of all attribute 
preference weights are consistent with a priori expectations, implying preferences for a lower 
medical burden and higher clinical efficacy given the attribute variable coding. The positive 
treatment specific constant implies that even the worst possible hypothetical treatment, with 
maximum burden and minimum efficacy, is preferable to no treatment. Comparing the pooled 
HCL model with the test and retest MNL models, the chi-square value is 6.361 (=–2*([–258.84] 
–  ([–145.97] +[–109.69])), p=0.384 on 6df). Hence we are unable to reject the null of equality 
of marginal utilities between the test and retest samples. Furthermore, the estimated scale term in 
the HCL model is not significantly different from zero, implying that the error variance does not 
differ significantly between the two samples. This finding is confirmed by the chi-square value 
of 0.051 (=–2*([–258.86] –  [–258.84]), p=0.823 on 1df) from a comparison of the pooled MNL 
and HCL models. Similar results are obtained if the choice model samples are expanded to 
include respondents with lexicographic choices and/or failed validity tests (see Supplementary 
Table 2). 
 
Determinants of choice consistency 
Choice consistency is modelled as a function of choice task difficulty and choice set positioning.  
Figure 1 shows that the agreement rate is negatively correlated with entropy: the probability of 
repeating a particular choice is higher, ceteris paribus, in a choice set with more dissimilar 




Figure 2 shows that there is a weak positive association between agreement rate and average 
choice set position.  
 
Table 4 reports average partial effect estimates from the choice consistency model. We focus on 
the results for the sub-sample of respondents who passed both validity tests in both DCEs as 
these provide the stronger statistical evidence of the existence of ordering effects. Thus, a unit 
increase in entropy leads to a significant decrease of 0.596 in the probability of a consistent 
choice, implying a 33.3% (=−100*0.559*[−0.596]) difference in predicted agreement rates 
between the choice sets with the lowest and highest entropies. As expected, choice consistency 
increases as the options within a choice set become more dissimilar in terms of their probabilities 
of being chosen. The null of no ordering effects is rejected by a likelihood ratio test with a chi-
square value of 6.016. The probability of agreement rises by 0.013 if a choice set is presented 
one position later on average, holding position deviation constant, with the simplest such case 
being when the choice set appears in the same position in both test and retest DCE both before 
and after the change. Noting that the complete DCE consists of 14 not 12 choice sets, the 
predicted agreement rate is 18.2% (=14*0.013) higher if a choice set appears last rather than first 
in both DCEs. There is also weak evidence of diminishing marginal ordering effects with a unit 
increase in position deviation leading to a 0.068 fall in the probability of a consistent choice 
holding average position constant, implying a maximum negative effect on the predicted 
agreement rate of 16.5% (=100*2.42*0.068 where 2.42= (196 1) / 2 (14 1) / 2+ − + ) when the 
choice set appears first in one DCE and last in the other. The use of the alternative measure of 
task difficulty does not lead to any substantive changes in the findings, with a 31.3% 
(=100*0.929*0.337) difference in predicted agreement rates between the choice sets with the 





This study adds to the limited evidence currently available on the temporal stability of patients’ 
treatment preferences. In particular, we provide the first investigation of this issue that has to our 
knowledge been conducted as an integral part of a clinical trial.  
 
With regard to choice consistency, the strength of agreement between the options chosen by 
patients at the start and end of the clinical trial is only moderate. Some additional insight is 
provided by the direct comparison of agreement rates for the repeated choice set in the DCE, 
with the average within-test rate of 91% higher than the between-test rate of 80% for the same 
decision task. A one-sided hypothesis test provides no evidence of a lower degree of between-
test than within-test consistency (z=−1.397; p=0.919), such as might result inter alia from a 
shift in patients’ treatment preferences. 
 
Nevertheless, the inability to demonstrate evidence of preference parameter changes is perhaps 
surprising given contrary indications from other studies. In particular, Serra-Guillen et al. report 
that only 72% of AK patients treated in an RCT with one of the topical treatments tested in the 
SPOT trial would have been willing to repeat the treatment despite informed consent having 
been obtained from all participants.26 More generally, studies of a range of healthcare services 
have found significant differences in preference patterns between groups with different levels of 
prior experience.8,27,28 In our study most participants had received treatment for AK beforehand, 
with a majority having already received one or more topical treatments for the condition. It is 
therefore plausible that they maintained the same preferences as they were already reasonably 





Choice consistency is found to be negatively related to choice task difficulty, corroborating the 
findings of previous non-healthcare studies that have also shown large predicted differences in 
agreement rates between choice sets depending on task difficulty.3 Intuitively, the harder the task 
the less likely that the same option will be chosen again when respondents are uncertain about 
their choices. Olsen et al argue that DCEs should contain a mix of tough and easy choice sets to 
ensure both the accuracy and precision of preference parameter estimates,29 where the inclusion 
of some easy tasks should also help ensure their stability if preferences do not in fact change. We 
also obtain weak evidence of the existence of ordering effects, with the finding of positive but 
diminishing marginal effects consistent with the results of studies showing choice uncertainty to 
be greatest in the first few choice sets in a DCE,13 possibly as the result of a positive but 
decreasing influence of learning through the sequence of choice sets.29,13 Our randomisation of 
choice set position was specifically designed to mitigate against bias in preference parameter 
estimates due to learning or fatigue.   
 
The study has a number of potential limitations. First the sample size may be too small to detect 
choice model parameter differences between the test and retest samples. However, further 
analysis shows the tests to be sufficiently powerful to detect significant differences in both 
preference and scale parameters between the similarly-sized OTR and ICP samples in the 
baseline assessment (see Supplementary Table 2): OTR patients may be expected to have a 
stronger preference for treatment given an approximately 100-fold increased risk of developing 
skin cancer.31 Using the de Bekker-Grob et al sample size calculation 30 with initial beliefs about 
parameter values given by the pooled MNL estimates, both the test and retest sample sizes are 
sufficient to reliably detect preference differences between attribute levels at the 5% significance 




experience, if any, by treatment arm on preference stability. Second, the findings on population-
level preference parameter stability may be sensitive to the choice model specification, but 
Kopasker et al. report robust estimates across a range of alternative logit specifications.15 Finally, 
our findings are based on a single clinical trial of topical treatments for AK and may not be 
generalisable to trials of the same condition in other settings or of other conditions. 
 
Conclusion 
The routine incorporation of DCEs into clinical trials would generate information on patient 
treatment preferences to complement existing cost effectiveness analyses in helping shape 
clinical guidelines. This study is the first to examine the temporal stability of preferences within 
the context of a clinical trial, finding no evidence of population-level preference changes despite 
only a moderate degree of choice consistency. However, further studies are required to firmly 
establish the effect, if any, of DCE timing within a trial on preference parameter estimates, with 
prior treatment experience a potentially significant determinant of whether preferences are stable 
or not. The random assignment of participants to different treatment arms in an RCT provides an 
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No responses - - - - -  - 1 1 
Failed rationality test only 2 1 - - -  - - 3 
Failed consistency test only 1 - - 1 -  - 1 3 













Lexicographic choices 5 - - 1 -  1 6 13 
Trader 6 2 1 - -  5 13 27 
  
Total 14 4 1 2 0  7 21 49 
 
DCE indicates discrete choice experiment; Failed both tests, failure of both rationality and consistency tests; Failed consistency test 
only, failure to choose the same option in the repeated decision task; Failed rationality test only, choice of dominated option in the 
rationality test choice set; Lexicographic choices, choosing the option that was the best with respect to one particular attribute in all 12 






Table 2. Main choice set agreement rates 
  Subgroup analysis 
  Failed at least 
one test in at 
least one 
assessment 
Passed both tests in both assessments 
 
All respondents to 
both assessments 
Lexicographic 
choices in at least 
one assessment 
‘Trader’ in both 
assessments 
Number of respondents 30 5 12 13 
Number of choice sets 360 60 144 156 
Agreement  rate (%) 73.1 68.3 72.9 75.0 
Cohen’s Kappa 0.469 0.388 0.466 0.504 
Number of choice sets per person 12 12 12 12 
Agreement per person (mean) 8.77 8.20 8.75 9.00 
Agreement per person (minimum) 4 4 6 5 
Agreement per person (maximum) 11 11 11 11 
DCE indicates discrete choice experiment; Failed at least one test in at least one assessment, failure of at least one of the rationality 
and consistency tests in at least one of the test and retest assessments; Lexicographic choices in at least one assessment, choosing the 
option that was the best with respect to one particular attribute in all 12 main choice sets in at least one assessment; trader in both 
assessments, choices revealed a willingness to trade gains in one attribute against losses in another at the levels specified in the DCE 




Table 3. Choice model estimation results  
 








Attributes     
Regimen: (reference level twice daily for 12 weeks)     
 Daily for 1 week 
 
0.726**  
(0.168)     






Local skin reaction: (reference level severe)     








Systemic effects: (reference level flu-like symptoms)     
 No other side effects  0.625** 
(0.170) 






Skin appearance: (reference level moderate improvement)     








Cancer risk: (reference level 20% fall)     








     








     
Treatment specific constant 16.667** 
(0.418)    
15.598** 
 (0.459)    
19.681** 
 (1.039)    
16.264** 
 (0.309)    
     Logarithm of relative scale parameter between assessments   0.038      
  (0.215)    
 
Number of observations† 972 753 1725 1725 
Number of respondents 27 21 48 48 
Log-likelihood -145.97 -109.69 -258.83 -258.86 
HCL indicates
 
heteroscedastic conditional logit; MNL, multinomial logit.
 
†One respondent failed to indicate a preferred option in one choice set in the retest assessment.  





Table 4. Panel fixed effects probit model of choice consistency 
Average partial effects 
Sub-sample passing both 
validity tests in both assessments 
Sub-sample with responses 
in both assessments 
         
     
 ENTROPY −0.596**  -   −0.517** -   
 (0.130)        (0.115)         
 [0.000]        [0.000]         
     
 UDIFF -   0.337** -    0.309**  
     (0.080)      (0.073)      
    [0.000]        [0.000]    
     
 POSAV 0.013       0.013     0.010       0.010      
 (0.008)      (0.008)     (0.008)     (0.008)     
 [0.116]     [0.113]     [0.202]     [0.210]       
     
 POSDEV −0.068       −0.073      −0.055       −0.059      
 (0.042)     (0.042)     (0.039)     (0.039)       
 [0.102]      [0.082]     [0.160]     [0.131]     
     
Number of observations 300       300       360       360       
Number of respondents 25        25        30        30        
Log-likelihood −138.51       −141.58       −172.14       −174.12       
Pseudo-R2 0.194       0.177       0.179       0.170       
χ2 test of no ordering effects on 2df 6.016*     6.426*       4.238      4.500      
 [0.049]     [0.040]     [0.120]       [0.105]    
ENTROPY indicates choice set entropy; POSAV, average choice set position; POSDEV, deviation 
in choice set position; UDIFF, predicted utility difference. 
Respondent fixed effects not reported.  
Robust respondent-clustered standard errors (in round brackets).  p-values in [square brackets]. 




Figure 1.  Choice consistency by choice set entropy  
 
 













































Supplementary Table 1  
Patients’ characteristics at baseline assessment 
 
Patient Characteristic 




Dropouts and non- 
respondents (n=18) 
p-value 
Age 64.40 [45.83-82.44] 63.87 [50.45-73.73] 65.38 [45.83-82.44]       0.542a 
Male 79.59%  (39) 74.19%  (23) 88.89%  (16) 0.227a  
Age first left education 
  
0.746b 
16 years or less 38.78% (19) 32.26%  (10) 50.00%  (9)  
17-19 years old 26.51% (13) 29.03%  (9) 22.22%  (4)  
20 years or over 32.65% (16) 35.48%  (11) 27.78%  (5)  
Not supplied   2.04% (1)   3.23%  (1)   0.00% (0)  
Time since most recent diagnosis 
 
0.069b 
Less than 1 day   2.04% (1)   0.00% (0)   5.56% (1)  
Less than 3 months 10.2% (5)   9.68% (3) 11.11% (2)  
Between 3 months and 1 
year   6.12% (3)   0.00% (0) 16.67% (3) 
 
Between 1 and 3 years   0.00% (0)   0.00% (0)   0.00% (0)  
Between 3 and 10 years 36.73% (18) 35.48% (11) 38.89% (7)  
More than 10 years 42.86% (21) 51.61% (16) 27.78% (5)  
Not supplied   2.04% (1)   3.23% (1)   0.00% (0)  
Self-rated seriousness of AK condition 0.251b 
1. Not serious   2.08% (0)   3.23% (1)   5.88% (1)  
2   8.33% (4)   9.68% (3)   0.00% (0)  
3 31.25% (15) 35.48% (11) 23.53% (4)  
4. Moderately serious 27.08% (13) 22.58% (7) 35.29% (6)  
5 20.83% (10) 19.35% (6) 23.53% (4)  
6   4.17% (2)   0.00% (0) 11.76% (2)  
7. Very serious   6.25% (3)   9.68% (3)   0.00% (0)  
Previous treatment for AK  85.71% (42) 90.32% (28) 77.78% (14) 0.235a 
Past cryotherapy 67.35% (33) 70.97% (22) 61.11% (11) 0.489a 
Past photodynamic therapy 12.24% (6) 12.90% (4) 11.11% (2) 0.857a 
Past Diclofenac gel   4.08% (2)   6.45% (2)   0.00% (0) 0.281a 
Past skin surgery 38.78% (19) 29.03% (9) 55.56% (10) 0.069a 
Past 5-fluorouracil cream 46.94% (23) 54.84% (17) 33.33% (6) 0.152a 
Past imiquimod cream 26.53% (13) 29.03% (9) 22.22% (4) 0.612a 
Past other treatment 14.29% (7) 16.13% (5) 11.11% (2) 0.637a 
Past treatment not known   6.12% (3)   6.45% (2)   5.56% (1) 0.902a     
 
DCE difficulty (5=highest)   2.85 [1-4]   2.80  [1-4]   2.94  [1-4] 0.622a 
DCE indicates discrete choice experiment.  
Continuous variables show mean and range [in square brackets]. Dummy variables show percentage and 




Supplementary Table 2 
Choice model parameter stability tests for alternative sub-sample comparisons 
χ2          







OTR Traders in test DCE  vs. OTR Traders in retest DCE 6.361 0.051 
(n=27)  (n=21) [0.384] [0.823] 
All OTR passed both tests in test 
DCE  
vs. 
All OTR passed both tests in retest 
DCE 11.965 2.006 
(n=40)  (n=28) [0.063] [0.156] 
OTR traders & failed at least one 
test in DCE  vs. 
OTR traders & failed at least one test 
in DCE 6.570 0.113 
(n=35)  (n=24) [0.362] [0.737] 
All OTR respondents in test DCE  vs. All OTR respondents in retest DCE  7.002 1.624 
(n=48)  (n=31) [0.321] [0.203] 
     OTR Traders in test DCE  vs. ICP Traders in test DCE 15.194* 6.366* 
(n=27)  (n=31) [0.019] [0.012] 
DCE indicates discrete choice experiment; Failed at least one test, failure of at least one of the 
rationality and consistency tests; ICP, immunocompetent patients; LR, likelihood ratio; OTR, 
organ transplant recipients; Passed both tests, pass in both the validity tests; Trader, choices 
revealed a willingness to trade gains in one attribute against losses in another at the levels 
specified in the DCE.  
p-values in [square brackets]. *p<0.05.  
 
 
